Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Structure Therapeutics Raises $33 Million for Novel Small Molecule Drugs

publication date: Aug 2, 2022

Structure Therapeutics, a San Francisco-Shanghai company, completed a $33 million addition to its $100 million Series B round, announced last October. Previously, Structure was known as ShouTi Inc. The company’s new name reflects its plan to build a portfolio of next-gen small molecule drugs based on structural design that overcome the limitations of biologics and peptide therapies. Structure’s initial efforts target the GPCR cell surface family of drug targets. Its lead molecule, GSBR-1290, is an oral small molecule GLP‐1 receptor agonist aimed at type 2 diabetes mellitus and obesity. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital